Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

Core Viewpoint - Capricor Therapeutics is set to release its financial results for Q4 and the full year of 2025 on March 12, 2026, and will host a conference call to discuss these results [1] Company Overview - Capricor Therapeutics (NASDAQ: CAPR) is focused on developing cell and exosome-based therapeutics aimed at treating rare diseases, with its lead product candidate being Deramiocel, a therapy for Duchenne muscular dystrophy (DMD) [3] - Deramiocel is in late-stage development and has shown significant immunomodulatory and anti-fibrotic effects in preserving cardiac and skeletal muscle function in DMD patients [3] - The company is also utilizing its proprietary StealthX™ platform for preclinical development in vaccinology and targeted delivery of therapeutics [3] Recent Developments - Capricor has entered into an exclusive commercialization and distribution agreement for Deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [6]